| 1 |
35526308 | A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. | 2022 Jul |
1 |
| 2 |
33753566 | Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages. | 2021 Mar |
1 |
| 3 |
34146911 | RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody. | 2021 Aug |
1 |
| 4 |
34371308 | Corrigendum to "RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody" [Eur. J. Radiol. 141 (2021) 109823]. | 2021 Sep |
1 |